New Report by BioTrends Explores the Unmet Need for Treatments Related to Proliferative and Non-Proliferative Glomerulonephritis

EXTON, Pa.--(BUSINESS WIRE)--Results of a survey of 100 U.S. nephrologists suggest that the need for new therapies targeted at glomerulonephritis (GN) is extremely high, with only polycystic kidney disease having significantly higher unmet need.

Nephrologists estimate that close to 10% of the patients they are managing have GN with focal segmental glomerulosclerosis (FSGS), membranous nephritis and IgA nephropathy accounting for approximately two-thirds of the cases. FSGS was associated with the highest unmet need resulting from a lack of effective treatments coupled with a high proportion of patients that are refractive to available treatments. Although they are fewer in number, patients with Goodpasture’s or blood vessel diseases (such as Wegener’s and vasculitis) are more likely to have rapid progression of chronic kidney disease, making treatment more urgent.